论文部分内容阅读
[目的]观察4个CEF 100序贯4个多西紫杉醇新辅助化疗方案对局部晚期乳腺癌(LABC)的近期疗效。[方法]2002年4月~2005年1月,在法国土鲁兹的Claudius Regaud Institute肿瘤中心,45例均有组织学诊断证实的局部晚期乳腺癌给以行新辅助化疗,化疗方案为4个周期的CEF 100(Epirubicin 100 mg/m2,5-Fu 500 mg/m2,Cyclo-phosphamide 500 mg/m2),每3周为1个周期,然后序贯4个周期的多西紫杉醇(100 mg/m2),每3周为一个周期,共8个周期。[结果]4个CEF100方案后临床CR11例(24%),PR18例(40%),临床有效率为(CR+PR)64%,SD16(36%)例。序贯多西紫杉醇化疗后临床CR 27例(60%),PR 13例(29%),总有效率为89%,SD 4例(9%),PD 1例(2%)。26例实施了保乳手术,保乳率为57.8%,29例进行了根治手术。病理完全缓解pCR 16例(36%)。[结论]CEF 100序贯多西紫杉醇的新辅助化疗方案以及8个周期的新辅助化疗具有更高的临床缓解率以及病理完全缓解率。
[Objective] To observe the short-term curative effect of 4 CEF 100 sequential 4 docetaxel neoadjuvant chemotherapy on locally advanced breast cancer (LABC). [Method] From April 2002 to January 2005, 45 patients with histologically confirmed locally advanced breast cancer were treated with neoadjuvant chemotherapy in the Claudius Regaud Institute Cancer Center, Tuluz, France. The chemotherapy regimens were 4 Cyclophosphamide 500 mg / m2) for 1 cycle every 3 weeks followed by sequential 4 cycles of docetaxel (100 mg / m2, 5-Fu 500 mg / m2) m2) every 3 weeks for a cycle, a total of 8 cycles. [Results] The clinical outcomes of CR11 (24%) and PR18 (40%) after 4 CEF100 regimens were (CR + PR) 64% and SD16 (36%). After sequential docetaxel chemotherapy, 27 cases (60%) had clinical CR, 13 cases (29%) had a total effective rate of 89%, 4 cases (9% SD) and 1 (2%) PD. Twenty-six patients underwent breast-conserving surgery with a rate of 57.8%, and 29 patients underwent radical surgery. Pathologic complete remission of pCR in 16 cases (36%). [Conclusions] Neoadjuvant chemotherapy with sequential docetaxel and CTC-100 neoadjuvant chemotherapy with 8 cycles have higher clinical remission rate and complete remission rate.